UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000045573
Receipt number R000051992
Scientific Title Study on sleep-improving effects by test-food intakes
Date of disclosure of the study information 2022/10/01
Last modified on 2022/09/26 11:49:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on sleep-improving effects by test-food intakes

Acronym

Study on sleep-improving effects by test-food intakes

Scientific Title

Study on sleep-improving effects by test-food intakes

Scientific Title:Acronym

Study on sleep-improving effects by test-food intakes

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify sleep-improving effects by test-food intakes for two weeks

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Sleeping condition measured by electroencephalograph (sleep-scope)

Key secondary outcomes

1. Oguri-Shirakawa-Azumi sleep inventory ver. MA
2. MOS 36-Item Short-Form Health Survey version2 (acute version)
3. Cortisol and alpha-amylase in saliva


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Consumption of the test food to the subjects, two a day for 2 weeks.

Interventions/Control_2

Consumption of the placebo food to the subjects, two a day for 2 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Healthy male/female subjects with unsatisfactory sleep, ranging in age from 20 to 64 at informed consent.
(2) Subjects having the habit of going to bed by 24 o'clock.
(3) Subjects taking in a staple food for dinner every day.
(4) During the test period, subjects who can take the test foods daily after fifteen o'clock, two a day.
(5) Subjects who can receive the test foods twice a week.
(6) Subjects who can give informed consent to participate in this study, after being provided with an explanation of the protocol detail.

Key exclusion criteria

Subjects - -
(1) taking in sleep-affecting foods, not less than three times a week,
(2) who will take medicines which might affect the test (e.g., sleeping pill) during the test period,
(3) vaccinated within two weeks before this study, or planning to vaccinate during intaking of test-foods,
(4) with not less than 30.0 kg/m2 of BMI,
(5) with sleep-apnea syndrome,
(6) with previous medical history of sleep disorder,
(7) with a continuous medical treatment for sleep disorder,
(8) cannot use the sleep-scope during the test period,
(9) with an alcohol intake at the measurement of brain waves,
(10) with an overnight trip during the test period,
(11) with extremely irregular dietary habit/life rhythm,
(12) with a serious sleep-affecting rhinitis,
(13) with excessive alcohol intake,
(14) with the roomer planning to participate in this study,
(15) restricting their mealtimes to no more than once a day (not less than once a week), within the last month,
(16) with medical history of serious diseases,
(17) with pregnancy, possibly one, or lactating,
(18) with drug/food allergy (wheat, egg, milk),
(19) being fitted with a pacemaker,
(20) with sensitive skin, irritating by an adhesive tape,
(21) being under another clinical test (medicine or health food), or participated in that within the last 4 weeks, or will join that after the consent,
(22) who donated their blood components or blood (0.2 L) within the last month,
(23) who donated his blood (0.4 L) within the last 3 months,
(24) who donated her blood (0.4 L) within the last 4 months,
(25) being collected in total of his blood (1.2 L) within the last 12 months and in this study,
(26) being collected in total of her blood (0.8 L) within the last 12 months and in this study,
(27) being determined as ineligible for participation by the principal/sub investigator - - .

Target sample size

16


Research contact person

Name of lead principal investigator

1st name Fumiko
Middle name
Last name Nakamura

Organization

CPCC Company Limited

Division name

Clinical Support Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Ichinohe

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Nisshin Seifun Group Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 09 Month 22 Day

Date of IRB

2021 Year 09 Month 17 Day

Anticipated trial start date

2021 Year 10 Month 01 Day

Last follow-up date

2021 Year 12 Month 11 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 09 Month 27 Day

Last modified on

2022 Year 09 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000051992


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name